Search for information about a product,
therapeutic area or event

Search

Media, investors, advocacy organizations and others, please contact us here.

Rkd-newss FSGS

Exploring Clinical Trial Endpoints in FSGS: Spotlight on Proteinuria

Publications FSGS

The Humanistic Burden of Focal Segmental Glomerulosclerosis on Patients and Care‑Partners in the United States

View
Publications FSGS

Efficacy and Safety of ACE Inhibitor and Angiotensin Receptor Blocker Therapies in Primary Focal Segmental Glomerulosclerosis Treatment: A Systematic Review and Meta-Analysis

View
Publications FSGS Nephrology

Differentiating Primary and Secondary FSGS Using Non-Invasive Urine Biomarkers

View
Publications FSGS Nephrology

Clinical Characteristics and Histopathology in Adults With Focal Segmental Glomerulosclerosis

View
Publications FSGS Nephrology

Population Pharmacokinetic Analysis of Sparsentan in Healthy Volunteers and Patients with Focal Segmental Glomerulosclerosis

View
Publications FSGS Sparsentan

Sparsentan Clinical Trials in Glomerular Diseases: Defining Endpoints and a Path Forward in Light of the Parasol Initiative

View
Publications FSGS

Epidemiology and Burden of Focal Segmental Glomerulosclerosis Among United States Veterans: An Analysis of Veteran’s Affairs Data

View
Episodes FSGS Nephrology

Introduction to FSGS

Medical Information FSGS

PARASOL: Proteinuria and GFR as Clinical Trial Endpoints in Focal Segmental Glomerulosclerosis

Learn more
Publications FSGS Sparsentan

DUET: A Phase 2 Study Evaluating the Efficacy and Safety of Sparsentan in Patients with FSGS

View
Publications FSGS

Implications of Complete Proteinuria Remission at Any Time in Focal Segmental Glomerulosclerosis: Sparsentan DUET Trial

View
Publications FSGS

Study Design of the Phase 3 Sparsentan Versus Irbesartan (DUPLEX) Study in Patients With Focal Segmental Glomerulosclerosis

View